NCT00607906 - First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2007

Primary Completion Date

March 10, 2008

Study Completion Date

March 10, 2008

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

SB-756050 immediate release capsule

SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.

DRUG

SB-756050 modified release capsule

SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.

DRUG

Placebo

Subjects will also receive placebo capsules.

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis